United States

Perrigo Faces Securities Class Action Over Baby Formula Unit as Schall Law Firm Seeks PRGO Lead Plaintiffs

Image
Perrigo Faces Securities Class Action Over Baby Formula Unit as Schall Law Firm Seeks PRGO Lead Plaintiffs

SHERIDAN, WYOMING - December 08, 2025 - Investors in Perrigo Company plc (NYSE: PRGO) are weighing next steps after The Schall Law Firm announced a putative securities class action alleging the consumer healthcare company misled the market about the condition and turnaround costs of the baby formula business it acquired from Nestlé. The case highlights ongoing governance and disclosure risk around carved-out assets in regulated consumer categories.

Allegations Center on Underinvestment in Nestlé Baby Formula Business

Rare Disease Leaders Warn FDA: Innovation Needs Predictable Rules, Not One-Off Exceptions

Image
Rare Disease Leaders Warn FDA: Innovation Needs Predictable Rules, Not One-Off Exceptions

SHERIDAN, WYOMING - December 08, 2025 - After a year of mixed signals from U.S. regulators, rare disease executives and policy experts are urging the FDA to match its pro-innovation rhetoric with clearer, more consistent rules for approvals, arguing that uncertainty around evidence standards is starting to chill investment and slow the next wave of therapies.

Mixed Messages from an Activist, Rare-Disease-Friendly FDA

Under Commissioner Marty Makary and CBER director Vinay Prasad, the FDA has made high-profile statements in favor of easing market access for rare disease treatments and even floated a "plausible mechanism" pathway for ultrarare conditions. Yet in practice, sponsor experience has been uneven.

FDA's One-Trial Plan Could Rewrite Global Drug Development Economics

Image
FDA’s One-Trial Plan Could Rewrite Global Drug Development Economics

SHERIDAN, WYOMING - December 08, 2025 - The U.S. Food and Drug Administration is preparing a fundamental shift in its evidentiary standards for new drugs, with Commissioner Marty Makary signaling that a single pivotal trial could soon be sufficient for approval-a move that has roiled internal leadership, unsettled some regulators and analysts, and triggered immediate recalculations in biopharma portfolio models.

From Two Pivotal Trials to One: A Structural Break

FDA Clinical Hold on Denali's Brain-Penetrant Pompe Therapy Highlights First-in-Human Safety Scrutiny

Image
FDA Clinical Hold on Denali’s Brain-Penetrant Pompe Therapy Highlights First-in-Human Safety Scrutiny

SHERIDAN, WYOMING - December 08, 2025 - Denali Therapeutics is facing another regulatory setback after the U.S. Food and Drug Administration (FDA) placed a clinical hold on DNL952, its enzyme replacement candidate for Pompe disease, citing preclinical hypersensitivity signals and demanding protocol changes before the company can start Phase I studies.

FDA Flags Hypersensitivity Risk Before First Human Dosing

The clinical hold, disclosed in an SEC filing, stems from "hypersensitivity reactions" observed in mouse models. While the agency has not required additional non-clinical studies, it is insisting on a more conservative first-in-human plan. Denali has been asked to lower the proposed starting dose for DNL952 and implement "revised inclusion criteria, adjusted stopping rules and unspecified safety monitoring commitments" before the program can proceed.

Praxis Scores Phase II Win in Rare Epilepsies as Ulixacaltamide Tracks Toward 2026 FDA Filing

Image
Praxis Scores Phase II Win in Rare Epilepsies as Ulixacaltamide Tracks Toward 2026 FDA Filing

SHERIDAN, WYOMING - December 08, 2025 - Praxis Precision Medicines has doubled down on its neurology strategy with back-to-back updates: a Phase II win for its sodium current blocker relutrigine in rare developmental and epileptic encephalopathies (DEE) and a "successful" pre-NDA meeting for its essential tremor candidate ulixacaltamide, positioning the Boston biotech as a potential new commercial player in both ultra-rare epilepsy and movement disorders.

Relutrigine Study Stopped Early for Efficacy in DEE

Praxis has halted its mid-stage EMBOLD trial of relutrigine early, after an independent data monitoring board recommended the study "stop the study early for efficacy." The Phase II EMBOLD study is evaluating relutrigine in patients with DEE linked to SCN8A and SCN2A mutations, a small but highly underserved genetic epilepsy population with limited therapeutic options and high unmet medical need.

ACIP's Hepatitis B Birth-Dose Reversal Puts U.S. Newborn Vaccine Policy Under Strain

Image
ACIP’s Hepatitis B Birth-Dose Reversal Puts U.S. Newborn Vaccine Policy Under Strain

SHERIDAN, WYOMING - December 08, 2025 - The CDC's Advisory Committee on Immunization Practices (ACIP) has triggered a major shift in U.S. newborn immunization policy, voting 8-3 to delay the hepatitis B vaccine for infants born to hepatitis B-negative mothers from the traditional birth dose to two months of age, despite decades of evidence and CDC messaging that the shot is safe, effective and critical for long-term protection.

A Narrow Vote to Delay the Birth Dose for Some Newborns

Under the new recommendation, only babies born to mothers who test positive for hepatitis B-or whose status is unknown-would still receive the birth dose. For infants of mothers who test negative, the vaccine can be delayed until two months, effectively dismantling the universal birth-dose strategy that has been in place for about 30 years.

How In-House 3D Printing Turns Your Dental Lab from Vendor into Strategic Partner

Image
How In-House 3D Printing Turns Your Dental Lab from Vendor into Strategic Partner

SHERIDAN, WYOMING - December 08, 2025 - As more practices adopt chairside 3D printing, many clinicians worry quietly about what it means for long-standing dental lab relationships-but rather than replacing labs, in-house production is reshaping them into higher-value, more strategic partnerships built around clearly defined roles and shared digital workflows.

From Full Lab Dependency to Hybrid Production

For years, the dominant model in restorative and appliance production has been full lab dependency: every crown, bridge, model, surgical guide, night guard or retainer went out the door to a third-party provider. In that setup, "Lab controls your timeline. Lab controls your cost per case. Lab capacity limits your capacity. Emergency cases wait on lab availability."

How Chairside 3D Printing with SprintRay Rewrites the Economics of Restorative Dentistry

Image
How Chairside 3D Printing with SprintRay Rewrites the Economics of Restorative Dentistry

SHERIDAN, WYOMING - December 08, 2025 - Chairside 3D printing has moved from conference buzzword to everyday reality in U.S. dental practices, and SprintRay is positioning its ecosystem as a way for clinics to bring production in-house, compress treatment timelines, and turn same-day crowns into a strategic differentiator rather than a marketing slogan.

From Lab Dependency to In-Practice Production

At its core, "chairside" simply means producing the restoration in your own practice while the patient is still in your care, instead of sending cases to an external lab and waiting one to two weeks. Clinically, the workflow is familiar-examination, preparation, design and cementation remain the same-but the fabrication step moves from a third party you can't control to equipment in your operatory that you can.

CrazyGoodBuy.com Launch Targets Restaurant Capex Pain with One-Cent Daily Equipment Auctions

Image
CrazyGoodBuy.com Launch Targets Restaurant Capex Pain with One-Cent Daily Equipment Auctions

SHERIDAN, WYOMING - December 04, 2025 - Restaurant operators facing tight margins and rising equipment costs have a new digital sourcing option as CrazyGoodBuy.com officially launches with a combination of deeply discounted commercial kitchen gear and a weekday "one-cent" auction format aimed squarely at independent and multi-unit foodservice businesses across the United States.

Auction-Based Equipment Buying for Cost-Pressed Operators

At the core of the new platform is the CrazyGood Buy Daily Deal Auction, a simple but aggressive model designed to help operators access premium equipment without tying up unnecessary capital. Each weekday at 9:00 a.m. Eastern, the site lists a single piece of brand-new equipment-ranging from refrigeration and prep tables to cooking lines and bar essentials-with bidding starting at just one cent and running until 5:00 p.m.

Butler/Avcon Wins EASA and CAA Approval for Non-Halon Learjet Fire Extinguishers

Image
Butler/Avcon Wins EASA and CAA Approval for Non-Halon Learjet Fire Extinguishers

SHERIDAN, WYOMING - December 04, 2025 - Butler National Corporation's Avcon Industries has secured European Union Aviation Safety Agency (EASA) and UK Civil Aviation Authority (CAA) approvals for its non-halon portable fire extinguisher retrofit on Learjet cabins, giving operators a certified, drop-in path to meet the looming December 04, 2025 halon phase-out deadline. The new approvals extend an earlier FAA Supplemental Type Certificate (STC) and position Avcon as a one-stop regulatory solution provider for Learjet fleets operating across North America, the UK and Europe.

Halon Phase-Out Drives Urgent Retrofit Decisions